A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-12-02
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-19 (study day 37); relationship: Y
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-26 (study day 103); relationship: N
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-15 (study day 123); relationship: N
Data queries
No data queries.